Thermo Fisher Scientific Inc. $TMO Stake Trimmed by Geneva Capital Management LLC

Geneva Capital Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 50.5% during the third quarter, Holdings Channel.com reports. The fund owned 1,757 shares of the medical research company’s stock after selling 1,796 shares during the quarter. Geneva Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $1,186,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Keeler Thomas Management LLC boosted its holdings in Thermo Fisher Scientific by 0.9% during the third quarter. Keeler Thomas Management LLC now owns 1,928 shares of the medical research company’s stock worth $1,301,000 after purchasing an additional 17 shares during the last quarter. Tsfg LLC increased its stake in Thermo Fisher Scientific by 20.4% in the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after buying an additional 19 shares during the last quarter. Welch Group LLC increased its stake in Thermo Fisher Scientific by 1.8% in the 3rd quarter. Welch Group LLC now owns 1,089 shares of the medical research company’s stock valued at $735,000 after buying an additional 19 shares during the last quarter. Renasant Bank lifted its position in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after buying an additional 20 shares in the last quarter. Finally, Strengthening Families & Communities LLC boosted its stake in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after buying an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TMO. DZ Bank lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Friday, October 23rd. Evercore dropped their price target on Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating on the stock in a report on Wednesday, October 28th. Guggenheim initiated coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They issued a “buy” rating and a $740.00 price objective on the stock. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $690.00 to $760.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $683.64.

Get Our Latest Research Report on Thermo Fisher Scientific

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 24,546 shares of company stock valued at $15,479,192. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.2%

TMO opened at $691.56 on Tuesday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $727.56. The company’s 50-day moving average price is $672.40 and its two-hundred day moving average price is $557.23. The stock has a market cap of $256.24 billion, a price-to-earnings ratio of 28.29, a PEG ratio of 2.85 and a beta of 0.84. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. Thermo Fisher Scientific’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $5.79 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.92%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.